Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: A randomized trial in Type 1 and type 2 diabetic patients

Diabetic Medicine

Volumn 19, Issue 5, 2002, Pages 393-399

  Boehm, B O ^a   Home, P D ^b   Behrend, C ^c   Kamp, N M ^c   Lindholm, A ^c  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Glycaemic control; Insulin analogue; Insulin aspart; Premixed insulin; Twice daily regimen

Indexed keywords

GLUCOSE; HUMAN INSULIN; INSULIN ASPART;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED;

EID: 0036096925     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2002.00733.x     Document Type: Article

References (38)

1. Insulin administration
2. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus
3. Insulin analogs with improved pharmacokinetic profiles
4. Monomeric insulins obtained by protein engineering and their medical implications
5. Monomeric insulins and their experimental and clinical implications
6. Design of insulin analogues for meal-related therapy
7. Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27, AspB10, AspB28) on meal-related plasma glucose excursions in type 1 diabetic subjects
8. Improved postprandial glycemic control with insulin aspart: A randomized double-blind cross-over trial in type 1 diabetes
9. The effect of intensive treatment of diabetes and the development and progression of long-term complications in insulin-dependent diabetes mellitus
10. The effects of improved glycaemic control on complications in type 2 diabetes
11. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes mellitus
12. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
13. Pharmacokinetics and pharmaco-dynamics of a premixed formulation of soluble and protamine-retarded insulin aspart
14. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture
15. Recommendations guiding medical physicians in biomedical research involving human subjects
16. Commission of the European Communities CPMP working party on efficacy of medical products. Good clinical practice for trials on medicinal products in the European Community
17. The application of the principle of intention-to-treat to the analysis of clinical trials
18. Comparison of conventional twice daily subcutaneous insulin administration and a multiple injection regimen (using the NovoPen(tm)) in insulin-dependent diabetes mellitus
19. Continuous subcutaneous insulin infusion versus injection therapy: A randomized cross-over trial under usual diabetic clinic conditions
20. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus
21. Improved glycemic control with insulin aspart: A multicenter randomized double-blind crossover trial in type 1 diabetic patients
22. Improved postprandial glycaemic control with insulin aspart in type 2 diabetes patients treated with insulin
23. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: A randomized controlled trial
24. Use of insulin aspart, a fast-acting insulin analog, as the meal-time insulin in the management of patients with type 1 diabetes
25. Human insulin analog (insulin aspart, IAsp) is comparable to human insulin in Type 2 diabetes
26. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications
27. The postprandial state and the risk of atherosclerosis
28. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy
29. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy
30. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation
31. Injection-meal interval: Recommendations of diabetologists and how patients handle it
32. Timing of pre-meal insulins in diabetic patients on a multiple daily injection regimen. A questionnaire study
33. Interval between insulin injection and eating in relation to blood glucose control in adult diabetics
34. Are presently available insulin analogues clinically beneficial?
35. Roles of site and timing of the morning insulin injection in type I diabetes